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Althoughatopicdermatitis(AD)istheinitialstepofthe‘‘atopicmarch’’,aprogressionfromADtoasthma,
theunderlyingmechanismremainsunknown.SelectiveexpressionofIL-13intheskinofmicecausedanAD
phenotype resembling human AD, and the disorder was associated with enhanced production of thymic
stromal lymphopoietin (TSLP) in the AD skin with a systemic Th2 immunity. Here we show that IL-13
transgenic micewith AD had significantly enhancedlung inflammation,mucus hypersecretion,and airway
hyperresponsiveness (AHR) when sensitized and challenged by allergen. In addition, the level of TSLP was
significantly higher in acute AD than in chronic AD. Furthermore, elimination of TSLP signaling
significantly diminished the allergic asthma responses, immune cell production of Th2 cytokines (IL-4,
IL-13),andserumIgE.ThesestudiesindicatethatIL-13inducesADandatopicmarchviaaTSLPdependent
mechanism.
A
topic diseases, including atopic dermatitis (AD) and asthma, sharing similar genetic and environmental
risk factors, have increased in prevalence in recent decades, and now affect approximately 20% of the
population in the developed countries
1, 2. AD is a chronic pruritic inflammatory disease, and the patho-
genesis of AD includes disrupted epidermal barrier function, immunodysregulation, and IgE-mediated sens-
itization to food and environmental allergens. Allergic asthma is characterized by a Th2 dominant airway
inflammation and airway hyperresponsiveness (AHR) associated with airway remodeling. Recent multiple
cross-sectional and longitudinal studies strongly support a temporal pattern of progression from atopic der-
matitistoasthma,theso-calledatopicmarch
3–7.AcausallinkbetweenADandallergicasthmahasbeensupported
byclinical studiesshowingthat ininfants with AD,43% developedasthma and45% developedallergic rhinitis as
young children
7. AD has been considered a major risk factor for the development of asthma, with an increased
odds ratio in children with AD in several longitudinal studies compared with children without AD
8. Research on
the mechanisms of AD has been centered on the Th1-Th2 paradigm. Recently, the conceptual focus on under-
standingADhasincreasinglyshiftedtoincludingaprimarydefectintheepithelialbarrierasaninitialeventinthe
atopic march. Many studies in animal models demonstrate that epidermal barrier dysfunction can be caused by
repeated sensitization to allergens to the skin, which leads to phenotypes of atopic dermatitis, systemic sensitiza-
tion, increased risk of allergic rhinitis, lung inflammation and AHR
9, 10.
Thymic stromal lymphopoietin (TSLP), an epithelial-derived cytokine critical in Th2 immunity, has been
shown to be highly increased in human AD skin as well as in the blood of patients with AD
11, 12. Recent studies in
animalmodelssuggestthatkeratinocyte-producedTSLPmaybeinvolvedasalinkbetweenatopicdermatitisand
asthma.AlackoftheNotchsignalinginthemouseskinresultsinskin-barrierdefectsandsignificantelevation of
serum TSLP triggering bronchial hyperresponsiveness to inhaled allergens in the absence of epicutaneous aller-
gen sensitization
13. Induced expression of TSLP in mouse epidermal keratinocytes upon topical application of
calcemic analogue of vitamin D3 triggers AD and aggravates experimental allergic asthma upon ovalbumin
sensitization and challenge
14. These studies suggest that elevated serum levels of TSLP may be responsible for
the asthma phenotype in these models.
Interleukin 13 (IL-13), a critical cytokine in several human atopic disorders including asthma and allergic
rhinitis, is remarkably increased in acute and chronic eczematous skin lesions of patients with AD
15, 16.W e
previously showed that transgenic expression of IL-13 in the skin causes remarkable inflammatory cell infiltrates
(CD41, Langerhans cells, eosinophils and mast cells) and increased levels of IL-4 and IL-13 by CD41 cells of
draining lymph nodes, splenic cells, serum total IgE and IgG1 in the absence of epicutaneous allergen sensitiza-
tion. We observed that TSLP was robustly upregulated in keratinocytes of mice with AD, and the level of TSLP
was significantly increased in the AD skin of Tg(1) mice compared to Tg(2) mice
17. However, whether IL-13
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and whether upregulated TSLP in the skin is involved in the process
have not been investigated.
In this study, we tested the hypothesis that IL-13 induced atopic
dermatitis predisposes to increased susceptibility to allergen stimu-
lated inflammatory and asthmatic responses and TSLP signaling
plays an important role in this progression from AD to asthma.
We used the dermal transgenic IL-13-induced AD model in com-
bination with suboptimal Ova challenge after sensitization and
demonstrated that that only Tg(1) mice that developed AD had
enhanced lung inflammation and AHR and IL-13-induced AD and
increasedallergicasthmaresponsestoallergenisdependentonTSLP
signaling.
Results
IL-13-inducedADisassociatedwithenhancedlunginflammation
upon suboptimal allergen challenge. We previously showed
that selective expression of IL-13 in the skin induces an atopic
dermatitis like phenotype characterized by intense pruritus,
erythema, and erosions in the acute phase, and dry, lichenified
skin in the chronic phase with skin remodeling and prominent
dermal Th2-inflammatory infiltrates. The AD was associated with
asystemicTh2environmentincludingincreasedlevelsoftotalserum
IgE and production of IL-4 and IL-13 by CD41 cells from draining
lymph nodes (DLN) and splenic cells
17.
In the present study, we investigated whether IL-13-induced AD
and the associated systemic Th2 environment would render
increased susceptibility to allergic asthma. To test this, we used a
modified suboptimal Ova-induced asthma protocol, in which 2,
instead of 3, consecutive airway inhalations of allergen were used
for challenge after sensitization. Tg(2) mice and Tg(1) mice that
developed AD (with a clinical score # 2;
17 ) were sensitized (days 0
and 7) via intraperitoneal (i.p.) injections of Ova and Alum and
challenged with two doses of inhaled Ova on days 21 and 22. The
control mice were injected i.p. with Alum alone and challenged with
vehicle PBS (Figure 1a).
There were rare inflammatory cells noted in PBS-challenged
Tg(2) and PBS-challenged Tg(1) lungs (Figure 1b). Remarkable
inflammatory cells were accumulated in peribronchial and perivas-
cular areas in the lungs of Ova-challenged Tg(1) mice compared to
Ova-challengedTg(2)mice.Alcianbluestainingofthelungsections
showed strong positive acidic mucus producing goblet cells (sky
blue) in the airways of Ova-challenged Tg(1) mice compared to
those in the airways of Ova-challenged Tg(2) mice (Figure 1c).I n
addition,thetotalinflammatorycellscollectedfrombronchiallavage
fluids (BAL) (Figure 1d) and the numbers of eosinophils, lympho-
cytes and macrophages were significantly higher in Ova-challenged
Tg(1) mice than those in Ova-challenged Tg(2) mice (Figure 1e).
The numbers of total and differential cells in BAL fluids were com-
parable among Ova-challenged Tg(2) mice and PBS-challenged
Tg(1) and Tg(2) mice. These data showed that Tg(1) mice that
hadADdevelopedenhanced lunginflammation tosuboptimalaller-
gen challenge, in contrast to Ova-challenged Tg(2) mice that did
not mount significant lung inflammation. Accordingly, the levels of
IL-4 and IL-13 were increased in the BAL fluids of Ova-challenged
Tg(1) mice compared to those of Ova-challenged Tg(2) mice
(Figure 1f, 1g), but the levels of IFN-c were comparable among all
groups (Figure 1h).
IL-13-induced AD is associated with enhanced airway resistance
upon suboptimal allergen challenge. AHR is one of the cardinal
features in human asthma and in experimental asthma. We used
both invasive and noninvasive pulmonary function test (PFT)
techniques to determine alterations in airway physiology of the
mice in response to increasing doses of methacholine after allergen
challenge (protocol in Figure 1a). Ova-challenged Tg(1) mice with
AD began to exhibit significantly enhanced airway resistance (R)
(cmH2ONS/ml) at 12.5 mg/ml and 25 mg/ml of methacholine
(Figure 2a) and significantly reduced lung compliance (C)
(ml/cmH2O) at 50 mg/ml of methacholine compared to those of
Tg(2) mice challenged with Ova (Figure 2b), which was
comparable to PBS-control groups. Consistent with enhanced
AHR in the Ova-challenged Tg(1) mice measured by invasive
PFT, using a non-invasive PFT technique, an exaggerated AHR
(Penh) in the Ova-challenged Tg(1) mice was also demonstrated
in response to methacholine (Figure 2c).
Taken together, these studies demonstrated that suboptimal Ova
challenge to the airway was insufficient to cause lung inflammation
and AHR in Tg(2) mice, but sufficient to provoke significant lung
inflammation and AHR in Tg(1) mice that developed AD, indi-
cating that these mice had increased susceptibility to allergen
induced allergic asthma responses.
Atopic dermatitis is important for the development of AHR. We
next investigated whether Tg(1) mice without clinical AD, when
sensitized and challenged by Ova allergen, could also develop
enhanced AHR upon methacholine challenge. Tg(1) mice that
presented with clinical AD (clinical score .2) and Tg(1) mice
that did not show clinical AD (the IL-13 transgene was on for
,8 weeks) were sensitized and challenged per the protocol
(Figure 1a). Histologically, the skin samples of Tg(1) mice
without AD did not display significant skin inflammatory
response. Conversely, the skin samples of Tg(1) mice with AD
showed extensive inflammatory infiltrates (Figure 3a, 3b). Airway
hyperresponsiveness(Penh)wascomparedbetweenTg(1)micethat
did not develop clinical AD and Tg(1) mice that did in response to
increased doses of methacholine. Only Tg(1) mice with AD showed
exaggerated AHR at 25 and 50 mg/ml of methacholine (Figure 3c),
strongly indicating that AD is important for the development of
allergic asthma in this model. Increased levels of IL-13 could be
found in the serum of Tg(1) mice as compared to Tg(2) mice.
However, there was no significant difference in the serum levels of
IL-13 between Tg(1) mice with mild AD that developed AHR and
those Tg(1) mice without AD that did not exhibit AHR, suggesting
that serum IL-13 in these mice was not a determinant in inducing
atopic march (Figure 3d).
Differential expression of TSLP in IL-13-induced acute and
chronic lesions. We previous showed that TSLP was highly
expressed by keratinocytes in IL-13-induced AD skin
17. We further
characterizedthe expressionofTSLPintheskin atdifferent stagesof
AD and found that TSLP expressed by keratinocytes of Tg(1) mice
was robustly higher in the acute AD lesions (Clinical score # 2 and
inductionoftheIL-13transgene,10weeks)thanthatinthechronic
AD (Figure 4a). However, the serum levels of TSLP in Tg(1) mice
thatdevelopedADwerebarely detectable,similartotheserumlevels
of TSLP in Tg(1) mice without AD and to those in Tg(2) mice
(Figure 4b). These results suggest that the early exaggerated
production of TSLP in acute AD skin lesions might be important
for initiating the atopic march but may be not through serum TSLP.
TSLPR deficiency attenuates IL-13-induced AD. The role of TSLP
signaling in promoting Th2 inflammation in asthma and AD has
been recognized
11, 18–20. And its role in the atopic march has been
proposed
13, 14. However, whether TSLP plays any role in IL-13-
induce atopic march is not known. We investigated the
importance of the TSLP-TSLPR signaling pathway in AD and in
subsequent atopic march induced by IL-13. K5-tTA-IL-13 mice
carrying the wild type TSLP receptor gene Tg(1)/TSLPR(1/1)
and the null mutation of the TSLP receptor gene Tg(1)/
TSLPR(2/2) on a C57BL/6 genetic background were first
compared for clinical AD and skin inflammation. Lack of TSLP
receptor in IL-13 Tg(1) mice (Tg(1)/TSLPR(2/2)) resulted in
www.nature.com/scientificreports
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AD, than that of Tg(1) mice carrying wild type TSLPR (Tg(1)/
TSLPR(1/1)) (Figure 5a). In addition, Tg(1)/TSLPR(2/2) mice
showed milder AD in the early course of AD development (10 and
12weeks aftertransgeneinduction) thanTg(1)/TSLPR(1/1) mice.
But at the late stage (.14 weeks) this difference was not significant
(Figure 5b). Thus TSLP signaling is more important in the early
pathogenesis of IL-13-induced AD.
Histological examination of skin inflammation using H&E
revealed that Tg(1) mice lacking TSLPR (Tg(1)/TSLPR(2/2))
exhibited milder inflammatory infiltrates (Figure 5c) and lower
numbers of inflammatory cells compared to the AD skin samples
Figure 1 | IL-13 Tg mice with AD sensitized and challenged with Ova had significantly increased lung inflammation. (a) A modified experimental
protocolwasusedtodetectexaggeratedresponseinTg(1)micewithADtoinhaledOvachallenge.K5-tTA-IL-13(Tg)(1)micethatdevelopedAD(AD
score.2) andtheir Tg(2) littermates were tested and compared. (b) Lung histology (H&E) showing increased infiltrating cells inthe peribronchialand
perivascularareasofthelungfromOva-challengedTg(1)mice,predominanteosinophilsandmononuclear cellsascomparedtoTg(2)mice.(c)Alcian
bluestainingoflungsectionsshowing mucusproducinggobletcells(skyblue).Mucusmetaplasiawasmore prominent inthe airwaysofOva-challenged
Tg(1) mice than that in the airways of Ova-challenged Tg(2) mice. (d) BAL total cell counts. Significant increases in the number of total inflammatory
cells collected from BAL fluids in Ova-challenged Tg(1) mice and (e) BAL cell differential. Significantly increased eosinophils, lymphocytes and
macrophages compared to Ova-challenged Tg(2) mice. (f) IL-4 levels, (g) IL-13 levels, and (h) IFN-c levels in the BAL samples from Tg(1) and Tg(2)
mice. (*P , 0.05; **P , 0.01; n510 mice for each group).
www.nature.com/scientificreports
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clonal antibodies against CD4and F4/80 (BM8) for detecting CD41
cells and activated Langerhans cells/macrophages, respectively,
significantly lower numbers of CD41 cells and Langerhans cells
were found in the AD skin samples from Tg(1)/TSLPR(2/2) mice
compared to Tg(1)/TSLPR(1/1) mice (Figure 5e, 5f). Using
Toluidine Blue staining for detecting mast cells and H&E staining
for detecting eosinophils, the numbers of mast cells and eosinophils
were also significantly reduced in the AD skin samples of Tg(1)/
TSLPR(2/2) mice compared to those in the AD skin of Tg(1)/
TSLPR(1/1) mice (Figure 5g and Table 1). These studies demon-
strated that TSLP signaling is vital for the severity of IL-13-induced
AD by regulating inflammatory cells critical for the pathogenesis of
AD. Deficiency of TSLPR in IL-13 mice did not alter the level of
dermal IL-13, however, indicating that alteration of dermal inflam-
mation by eliminating TSLPR in Tg(1) mice was not due to inhibi-
tion of the IL-13 transgene expression (Supplemental Fig. S1). The
levels of TSLP in the skin and in the serum of Tg(1)/TSLPR(1/1)
and Tg(1)/TSLPR(2/2) mice were not significantly altered either
(Supplemental Fig. S1).
TSLPR deficiency attenuates IL-13-induced atopic march. We
next investigated the role of TSLP signaling in IL-13 triggered
atopic march. Tg(1)/TSLPR(1/1) and Tg(1)/TSLPR(2/2)m i c e
that exhibited clinical AD (clinical score .2) and Tg(2)/TSLPR
(1/1) and Tg(2)/TSLPR(2/2) mice on C57BL/6 background as
controls were analyzed. After the mice were sensitized and
challenged with Ova or PBS per protocol in Figure 1a,l u n g
inflammation in peribronchial regions was significantly enhanced in
the Tg(1)/TSLPR(1/1) mice. Conversely, inflammatory cells in the
airway of Tg(1)/TSLPR(2/2)m i c ew e r ea t t e n u a t e d( Figure 6a, 6b).
Correspondingly, the number of total inflammatory cells collected
from BAL fluids and the numbers of eosinophils, lymphocytes and
macrophages were markedly decreased in Tg(1) mice deficient in
TSLPR (Tg(1)/TSLPR(2/2)) compared to those of Tg(1)m i c e
with wild-type TSLPR (Tg(1)/TSLPR(1/1)) (Figure 6c, 6d). The
levels of TSLP in the lung tissue and BALs of Tg(1)/TSLPR(1/1)
and Tg(1)/TSLPR(2/2) mice were not significantly altered in the
absence of the sensitization and challenge of allergen (Ova)
(Supplemental Fig. S1).
Using invasive PFT, airway resistance (R) and lung compliance
(C) in response to increased doses of methacholine were assessed.
Tg(1) mice carrying the wild type TSLPR manifested a heightened
AHR. In contrast, deletion of TSLPR in Tg(1) mice significantly
attenuated airway resistance (R) at 50 mg/ml and 100 mg/ml of
methacholine (Figure 7a). In accord with these findings, lung com-
pliance (C) was significantly improved in Tg(1) mice carrying null
mutationofTSLPR(Tg(1)/TSLPR(2/2))comparedtoTg(1)mice
carrying wild type TSLPR (Tg(1)/TSLPR(1/1)) (Figure 7b).
Figure 2 | IL-13 Tg(1)mice with AD sensitizedand challenged with Ova
had significantly worse lung functions. Using invasive pulmonary
function test (PFT), total airway resistance (R (cmH2ONs/ml)) and lung
compliance (C(ml/cmH2O)) atbaseline(vehicle alone;0)andinresponse
to increasing doses of methacholine (3.12, 6.25, 12, 25, and 50 mg/ml)
were assessed in Ova-challenged Tg(1) and Tg(2) mice and PBS-control
Tg(1) and Tg(2) mice one day after the last inhaled Ova challenge. (a) In
invasive PFT, Ova challenged Tg(1) mice that developed AD mounted
exaggerated airway resistance at 12.5 and 25 mg/ml of methacholine and
(b) exhibited reduced lung compliance at 50 mg/ml of methacholine after
a suboptimal Ova challenge, whereas, Ova-challenged Tg(2) mice did not
exhibit increased R and reduced C compared to PBS-control groups. (c)
Increased AHR (Penh) was also demonstrated in Ova treated Tg(1) mice
by noninvasive PFT. These measurements are confirmed in 2 more sets of
experiments. (*P , 0.05, **P, 0.01. n510 for each Ova group and n55
for each control group).
www.nature.com/scientificreports
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Tg(1) mice with wild type TSLPRhadsignificantlyincreased produc-
tion of IL-4 and IL-13 in the airways after suboptimal Ova challenge
compared to Tg(2) mice with or without TSLPR. In contrast, Tg(1)
mice with null mutant TSLPR had reduced levels of BAL IL-4 and
IL-13 after Ova challenge (Figure 7c, 7d). The levels of Th1 cytokine,
IFN-c in the airways were not altered among all groups (Figure 7e).
TSLPR deficiency diminished the systemic Th2 immune environ-
ment in IL-13 Tg(1) mice. To better understand the role of TSLP
signalinginIL-13 triggeredADand increasedsusceptibilitytoallergic
asthma, we determined the changes in the systemic Th2 dominated
immune environment by measuring the serum levels of IgE and the
production of Th2 and Th1 cytokines by immune cells in mice with
or without the null mutation in TSLPR. CD41 cells and lymphocytes
purified from spleen and draining lymph nodes (inguinal, subclavical
andaxillaryregions)wereactivatedbyanti-CD3/CD28for3daysand
Th2 cytokines (IL-4 and IL-13) and Th1 cytokine IFN-c were
measured and compared between Tg(1) mice carrying wild type
TSLPR and Tg(1) mice carrying null-mutated TSLPR.
Figure 4 | Association of IL-13-induced AD with alterations of the TSLP levels in the skin and in the serum. The levels of TSLP protein in the skin and
serum were assessed by ELISA. (a) Significantly higher levels of TSLP in the skin of Tg(1) mice than in Tg(2) mice and the difference was more
prominent in acute AD than in chronic AD. (b) Serum levels of TSLP in Tg(1) mice after induction of IL-13 transgene and compared with Tg(2) mice
receiving the same treatment. (**P, 0.01; n58 for Tg(2) group and n5 10 for each Tg(1) group).
Figure 3 | Relationship between onset of atopic dermatitis and the development of exaggerated AHR. Induction of IL-13 transgenic expression
was initiated for different time periods and the development of clinical and histological AD and its correlation with changes in lung physiology were
assessed. (a) Clinical AD scores of Tg(1) mice at different time after IL-13 induction, with Tg(2) mice as controls. (b) Histological examination (H&E)
showed greatly increased inflammatory infiltrate in the skin of Tg(1) mice with AD compared to minimal inflammatory infiltrates in Tg(1) mice
withoutAD.(c)Tg(1)micewithADshowedenhancedAHR(Penh)comparedtoTg(1)micethatdidnothaveADandtoTg(2)mice.(d)SerumIL-13
levels in Tg(2) mice and Tg(1) mice with or without AD. (*P , 0.05, **P, 0.01; n58–10 each Tg(1) group and n56 for each Tg(2) control group).
www.nature.com/scientificreports
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numbers of scratches per 30 min (Tg(2) mice n56; Tg(1) mice n58). (b) Clinical AD scores in the early stages of AD development were significantly
reducedinTg(1)/TSLPR(2/2)micecompared tothoseinTg(1)/TSLPR(1/1)mice(Tg(1)/TSLPR(1/1)micen54andTg(1)/TSLPR(2/2)mice
n58). (c) Histological evaluation of skin sections (H&E, 103) and (d) Quantitative evaluation of the inflammatory cells (high power field). (e) IHC
evaluation of CD41 cells with monoclonal anti-CD4 antibody and (f) Langerhans cells/Macrophages with monoclonal anti-F4/80 antibody.
(g) Toluidine blue staining for mast cells in the skin. Quantification of these cells, including eosinophil evaluation by H&E, is shown in Table 1. For all
comparisons, *P , 0.05, **P , 0.01.
Table 1 | Inflammatory Infiltration in the Skin
IL-13 221 1
Stain TSLPR 1/12 /21 /12 /2 P-Value
CD41 cells IHC 2.2260.12 1.9860.21 12.562.63 5.261.36* 0.012
F4/801 cells IHC 3.960.21 4.260.41 25.962.31 9.9862.96* 0.011
Mast cells TB 16.262.30 14.663.25 48.566.4 15.462.6* 0.01
Eosinophils H&E 0.5160.02 1.060.4 12.660.98 4.660.56* 0.02
N 647 5
Skin sections were stained with H&E, Toluidine blue (TB), or Immunohistochemistry (IHC) and the unit is the number of positive cells per high power field. Values are Mean6SEM. The values in all Tg(1)/
TSLPR(1/1) mice are significantly higher than Tg(2)/TSLPR(1/1) mice and Tg(2)/TSLPR(2/2) mice.
*Comparison between Tg(1)/TSLPR(1/1) mice and Tg(1)/TSLPR(2/2) mice.
www.nature.com/scientificreports
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serum total IgE and Ova-specific IgG1, whereas Tg(1) mice with
wild type TSLPR showed significantly increased levels of serum total
IgEandOva-specificIgG1.EliminationofTSLPRintheTg(1)mice,
however, resulted in reduced levels of serum total IgE and Ova-
specific IgG1 (Figure 8a, 8b). However, no difference was noticed
among all groups in the levels of Ova-specific IgG2a (Figure 8c).
Without any stimulation (medium control), lymphocytes and
CD41 T cells from all the groups did not produce detectable cyto-
kines (Figure 8d–i). Lymphocytes and CD41 T cells isolated from
Tg(2)/TSLPR(1/1) mice and Tg(2)/TSLPR(2/2) mice produced
significant but comparable levels of IL-4 and IL-13. But cells from
Tg(1)/TSLPR(1/1) mice produced significantly higher levels of
IL-4 and IL-13 compared to cells from Tg(2) mice (Figure 8d–g).
However, the levels of IL-4 and IL-13 produced by lymphocytes and
CD4
1 T cells from Tg(1) mice with null mutant TSLPR were sig-
nificantly lower than those by cells from Tg(1)/TSLPR(1/1) mice
(Figure 8d–g). On the other hand, the levels of IFN-c were not
significantly altered among the Tg(1) groups (Figure 8h, 8i).
When viewed together, these data suggest that the TSLP signaling
pathwayis criticallyinvolved inthe IL-13induced ADand increased
susceptibility to Ova induced allergic asthma by promoting IL-4 and
IL-13 production in spleen and lymph nodes leading to a systemic
Th2 conducive environment for further development of allergic
inflammatory responses to allergens.
Discussion
Multiple lines of evidence (clinical, genetic and experimental studies)
suggest that prior expression of atopic dermatitis is a prerequisite for
the development of allergic rhinitis and asthma, the process termed
theatopicmarch.The temporalpatterndescribedinthe atopicmarch
is strongly influenced by both genetic and environmental factors. The
main risk factors for progression and persistence of human asthma
are early onset, IgE sensitization, and severity of AD. Approximately
60–70% of children with severe AD develop asthma comparing to
20–30% of children with mild AD and only 8% in the general popu-
lation
7. The progression from AD to asthma is supported by studies
using mouse models demonstrating that epicutaneous sensitization
withovalbumininduceslocalized ADandAHRtomethacholineafter
challenge with aerosolized ovalbumin
9 and that epicutaneous aero-
allergen exposureinducessystemic Th2 immunitythatpredisposes to
allergic nasal responses, suggesting that the skin is a potent site for
antigen sensitization in the development of experimental allergic
rhinitis
21. Other murine models have shown that epicutaneous expo-
sure to ovalbumin and peanut after the removal of the stratum
corneum induces a strong systemic Th2 immune responses charac-
terized by elevated IL-4 secretion by T cells from draining lymph
nodes and by high levels of allergen specific IgE and IgG1
9, 22.T w o
recent studies using different models of AD suggested that TSLP may
be an important link between AD and increased susceptibility to
allergen stimulation in the airway
13, 14. We previously reported that
IL-13, when expressed in the skin, induced an AD-like disorder with
significant upregulation of TSLP in keratinocytes
17. In this study we
investigated whether IL-13-induced AD is associated with increased
susceptibility to allergen induced allergic responses in the lung and
whether TSLP plays any role in this process.
Here we show that transgenic expression of IL-13 in the mouse
skin not only induced AD but also led to significantly enhanced
Figure 6 | Deletion of TSLPR in Tg(1) mice attenuated IL-13-induced enhanced lung inflammation upon Ova challenge. After Ova sensitization and
challenge,inflammatoryresponsesinthelungofTg(2)/TSLPR(1/1),Tg(2)/TSLPR(2/2),Tg(1)/TSLPR(1/1)andTg(1)/TSLPR(2/2)micewere
assessed. (a) H&E evaluation (103) of lung tissue inflammation; (b) Quantification of inflammatory cells in lung tissue; (c) Total inflammatory cells in
BAL and (d) Cell differentials in the BAL fluids showing greatly reduced inflammatory responses in the Tg(1)/TSLPR(2/2) mice compared to the
Tg(1)/TSLPR(1/1) mice. (n58 mice for each Tg(2) groups and n510 for each Tg(1) group, *P , 0.05, **P , 0.01).
www.nature.com/scientificreports
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mucus hypersecretion and AHR upon suboptimal allergen challenge
in the airway. Importantly, skin AD lesions were directly related to
the development of enhanced airway responses. These findings were
accompanied by a heightened systemic Th2 immune status as
increased serum IgE and IgG1 and increased Th2 cytokine produc-
tion by peripheral immune cells could be seen in the Tg(1) mice
with AD.
IL-13 is a Th2 cytokine that has a prominent role in the patho-
genesisofallergicasthma.Inthepresentstudy,eventhoughtheIL-13
transgene was expressed selectively in the skin, increased levels of
IL-13 could be found in the serum samples of Tg(1) mice as com-
pared to Tg(2) mice. Thus it is essential to determine whether
systemic IL-13 was responsible for the generation of enhanced asth-
matic responses in these mice. Our analyses showed that although
the serum IL-13 levels were comparable, only Tg(1) mice that
developed AD had enhanced allergic responses to Ova challenge,
whereas Tg(1) mice without AD did not (Figure 3), suggesting that
serum IL-13 levels were not critical for the atopic march. On the
other hand, when TSLP signaling was interrupted by deletion of
TSLPR, the asthma phenotype in the Tg(1) mice was significantly
dampened, indicating that TSLP signaling was critical in the atopic
march in this system.
Ithasbeenreportedthatintradermaladministrationofrecombin-
ant TSLP promoted a systemic Th2 response, although its effects on
atopic march was not examined
23. In our study, the levels of TSLP
were significantly increased in the AD skin lesions, higher in the
acute AD than those in the chronic AD, suggesting that TSLP may
playavitalroleininitiatingsystemicTh2immunityfavorableforthe
development of atopic march. Indeed, when TSLP signaling was
blocked by genetic deletion of TSLPR, IL-13 Tg(1) mice showed
greatlyattenuated dermalinflammatory responses andreducedclin-
ical AD scores, although the difference was not readily seen in later
more severe chronic AD. Furthermore, Tg(1) mice deficient in
TSLPR exhibited significantly diminished capability of mounting a
rigorous lung inflammation and AHR upon Ova challenge. These
changes in the skin and in the airway were in parallel with reduced
systemic Th2 immune responses, including reduced IgE and Ova-
specific IgG1 and reduced Th2 cytokine production by peripheral
immune cells. These findings indicate that TSLP signaling is import-
ant for the early development of AD and critical in triggering the
atopic march, possibly through promoting peripheral lymphocyte
production of Th2 cytokines IL-4 and IL-13, which are critical for
thedifferentiationofTh2cellsandforthetissueresponsestoallergen
stimulation.
Increased levels of TSLP in the lesional skin of IL-13-induced AD
were described previously
17. Further analysis in this study showed
that this increase was more prominent in the acute phase than in the
chronic phase (Figure 4a). A critical role of TSLP signaling in IL-13-
induced AD and increased susceptibility to allergen stimulation was
demonstrated in the experiments using mice with TSLPR null muta-
tion. Unexpectedly, we could not detect any elevation in the TSLP in
Figure 7 | Deletion of TSLPR diminished IL-13-induced and AD related alterations in pulmonary physiology. Using invasive PFT, comparing to
Tg(1)/TSLPR(1/1)mice,theTg(1)/TSLPR(2/2)miceexhibited(a)reducedairwayresistanceR(cmH2ONs/ml)and(b)improvedlungcomplianceC
(ml/cmH2O). (c and d) These were associated with reduced levels of IL-4 and IL-13 in the BAL fluid by ELISA. (e)The levels ofIFN-c among the groups
were not significantly altered (* P , 0.05, ** P , 0.01; n58–11 for each group).
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acute AD showed peak levels of TSLP in the skin. The reason for this
is unclear. In a study with MC903 (a low calcemic analogue of vit-
amin D3) induced AD, Zhang et al. found that the increase of serum
TSLP peaked on day 4 after stimulation but significantly reduced by
day22
14.IntwostudiesbyDemehrietal.onmutantmicedeficientin
Notch signaling molecules and on K14-TSLP transgenic mice, high
levels of TSLP were found in the serum samples of these mice with
peakvaluesseeninyoungmice,butsignificantlylowerlevelsinadult
mice
13, 24. Thus, in these AD models there seems an optimal time
period of TSLP expression by keratinocytes and release into the
serum in younger mice or in early stimulation. As a product of
keratinocytes,particularlyindiseasestatus,TSLPisknowntobeable
to activate dendritic cells in situ and subsequently leading to allergic
inflammation that is not limited to the skin
11. Thus it is possible that
TSLP produced in the lesional skin of IL-13-induced AD stimulates
DCs, which then migrate to draining lymph nodes and lead to sys-
temic Th2 activation without changes in TSLP levels in the serum.
However, the exact mechanism remains to be investigated. In addi-
tion, the expression patterns of TSLP in the skin of Tg(2) mice and
inTg(1)micewithacuteandchronicADinourstudyareconsistent
with some of the above observations. We speculate that the kerati-
nocytes producing TSLP in the early AD are robust and responsive
and have high capacity in producing inflammatory cytokines.
However, at the later chronic stage, many of the keratinocytes may
have been damaged resulting in reduced capacity to produce cyto-
kines.Furthermore,deletionofTSLPRdidnotaffecttheIL-13trans-
gene expression in the skin nor the serum levels of IL-13 in Tg(1)
mice, suggesting that TSLP signaling, not IL-13 per se, is critical in
atopic dermatitis and atopic march in this model.
Figure 8 | Alterations of systemic Th2 immune responses to Ova allergen in Tg(1) mice with TSLPR deficiency. After sensitization and challenge by
Ova, serum samples and lymphocytes from Tg(2) and Tg(1) mice with TSLPR(1/1) or TSLPR(2/2) were harvested and evaluated. (a) Serum
totalIgE levelswere significantly reduced inthe Tg(1)/TSLPR(2/2)mice compared tothe Tg(1)/TSLPR(1/1) mice; (b)Serum levels ofOva-specific
IgG1; (c) Serum Ova-specific IgG2a. For evaluation of cytokine production CD41 cells from spleen and lymphocytes from cutaneous draining lymph
nodes were isolated and activated by a-CD3/CD28 for 3 days or medium as control. Cytokines in the supernatants were measured by ELISA. (d, e) IL-4
levels; (f, g) IL-13 levels; and (h, i) IFN-c levels. (n5 6–7 for each group; *P , 0.05, **P , 0.01).
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allergeninducedallergicasthmaresponses.AftertheusualOvasens-
itization, the mice were challenged through the airway with Ova 2
times, instead of 3 times used in usual protocols
18. As seen in this
study this protocol induces in normal mice a low degree airway
inflammationandnoenhancedAHR.However,underthiscondition
IL-13 Tg(1) mice with AD displayed full-blown airway inflam-
mation and enhanced AHR, suggesting increased susceptibility to
allergen stimulation in these mice.
Previous studies showed that TSLP signaling is required to mount
a normal CD41 T cell–mediated inflammatory response, and
TSLPR-deficient mice (on Balb/c genetic background) failed to
develop Th2 inflammatory lung response to inhaled antigen
18.I n
this study, we consistently found that the Tg(2)/TSLPR(1/1) and
Tg(2)/TSLPR(2/2) mice (C57BL/6 background) exhibited similar
low levels of inflammatory responses in the lung upon suboptimal
Ova challenge (Figure 7). This slight discrepancy between the two
studies is likely due to differences in the genetic background of the
mice used and in the challenge protocols in the studies.
Taken together, our studies clearly demonstrated that dermal
expression of Th2 cytokine IL-13 not only induces atopic dermatitis
but also predisposes to increased susceptibility to allergen-induced
allergic asthma; the onset of atopic dermatitis is important for the
development of atopic march; and by promoting a systemic Th2
environment the TSLP signaling is critical in the pathogenesis of
IL-13-induced AD and in the atopic march.
Methods
Animals. The externally inducible skin-specific IL-13 transgenic mice (K5-tTA-IL-
13(1)orsimplyTg(1)mice)onC57BL/6geneticbackgroundweregeneratedbyour
laboratory as previously described
17. To control the expression of IL-13 specifically
and inducibly in the skin, Doxycycline (Dox) was added to the drinking water
(1 mg/ml) to suppress tTA binding to its target and to keep the IL-13 transgene off,
starting from breeding until the K5-tTA-IL-13 mice were six weeks old. The
experiments were initiated by withdrawing Dox from the drinking water to activate
the IL-13 transgene. In all experiments, Tg(2) littermate controls received the
same amount of Dox or no Dox for the same length of time. The TSLPR gene null
mice were a kind gift from Dr. Warren Leonard from NIH as described previously
25.
These mice on C57BL/6 genetic background were crossbred with the K5-tTA mice
and TRE-Tight-IL-13 mice, both of which were on C57BL/6 background. The
genotype of the K5-tTA-IL-13 mice was determined as described previously
17. The
genotype of the TSLP receptor null mice was determined using three PCR primers
in one reaction: primer A, 59-AACCTCTCCCACAA GAAGTCCAGAAGT-39;
Neo primer, 59-ATCGCCTTCTATCGCCTTCTT-39; and primer B,
59-AGACTTTACCTGATTCCTGCCTTG-39. Primers A and B amplify a 250-bp
segment of the endogenous TSLPR gene. The Neo primer and primer B identify the
targeted gene and give a 650-bp product
25. The offspring with genotypes K5-tTA-
IL13/TSLPR(1/1) (or simply Tg(1)/TSLPR(1/1)) and K5-tTA-IL13/TSLPR
(2/2) (or simply Tg(1)/TSLPR(2/2)) were compared in the experiments. All
procedures involving animals in this study were approved by the Johns Hopkins
University Institutional Animal Care and Use Committee (IACUC).
Ova allergen sensitization and challenge and assessment of allergic asthmatic
responses.K5-tTA-IL-13(Tg)(1)micethatdevelopedADcarryingwildtypeornull
mutation of TSLPR and Tg(2) mice on C57BL/6 genetic background were used. The
inductionofIL-13expressionandADdiseasewasinitiatedbywithdrawingDoxfrom
thedrinkingwaterforallexperimentalgroups,whichwereatsimilarage.Theallergen
sensitization and challenge protocol was started at 10 weeks of induction and by
whichtime,theTg(1)micehadanADclinicalscoreofabout2.Totestwhetherthere
were enhanced allergic asthma responses, we utilized a modified Ova challenge
protocol with less strenuous stimulation with slight modification
18. After initial
sensitizationwithi.p.injectionofOva(100mg)withAlum(2 mg)(SigmaChemicals)
in 100 ml PBS on day 0 and day 7, the mice were intranasally (i.n.) challenged with
10 mg Ova in 50 ml PBS on days 21 and 22. For control groups, mice were i.p. injected
with Alum only and given PBS at challenge (Figure 1a). Mice were assessed for AHR
one day after the last dose of Ova challenge (day 23) using invasive PFT for airway
resistance (R)( cmH2ONs/ml) and lung compliance (C) (ml/cmH2O) using a small
rodent PFT apparatus flexiVent (SCIREQ Inc., Montreal, Canada). Airway
hyperresponsiveness (AHR) was also assessed by noninvasive whole body
plethysmography (Buxco) in response to inhaled methacholine (Sigma), using
enhanced pause (Penh) asanindex ofairway responsiveness
26.BAL fluids and serum
samples were collected from mice that underwent noninvasive PFT on day 24. After
lavage,lungswereexcisedcompletelyfromthechestcavity,inflatedwith10%neutral
bufferedformalin(FisherScientific)andfixedinthesamesolutionovernightatroom
temperature. Tissues were embedded in paraffin, sectioned at 5 mm, and stained with
H&E and Alcian blue.
Clinicaldiseaseanditchy/scratchingscores.Tg(1)andTg(2)micewereexamined
for skin lesions 3 times per week and the clinical scores for disease severity were
recordedasdescribedwithslightmodifications
17,21, 27.Acutedermatitiswasdefinedas
occurring less than 10 weeks after the transgene induction with a clinical score # 2
and chronic AD was defined as occurring 10 weeks after induction with an AD score
.2. The clinical manifestation of itching/scratching behavior of the mice was
videotaped 30 minutes/time,twiceaweekatthesame timeeachtime.Thescratching
behavior was counted for hind limb scratching directed towards the dermatitis areas.
One scratch was considered to be a lifting of the hind limb towards the dermatitis
areas and then a replacing of the limb back to the floor, regardless of how many
scratching strokes take place between those two movements as described previously
with slight modification
28.
Assessmentofairwayandlungtissueinflammation.BALcellularityincludingtotal
cell counts and cell differential were performed and lung tissue inflammation was
assessed using the morphometric approaches that have been described
26. Fifteen
different images of H&E-stained lung sections from 7 animals in each group were
captured at high power on an Olympus BX50 microscopy (Olympus America, NY,
USA). Thiswasaccomplished using a QImaging RetigaEXi Camera (from BioVision
Technologies, Inc, Exton, PA) with iVision Software (from BioVision Technologies,
Inc, Exton, PA). The infiltrating cells were counted in a 2003200 mm
2 area of the
bronchovascular bundles of randomly selected medium-sized airways. The data are
presented as Mean6SEM of cells per high power field (HPF).
Preparation of skin protein extracts and measurement of cytokines. Protein
samples from the skin were prepared as described previously
17. Briefly, frozen skin
tissues were placed in liquid nitrogen, crushed with a mortar and pestle and weighed.
Triton X-100 0.25% (wt/vol) in phosphate-buffered saline was added to the skin
powder. The homogenate was stirred at 4uC overnight and then centrifuged at
30003g for 15 minutes to remove debris. Supernatants were stored in small aliquots
at 280uC until assayed. All samples were normalized to the weight of the skin
samples. Cytokines in the skin samples were determined using ELISA kits per the
manufacturer’s instructions (R&D Systems, Minneapolis, MN).
Histology and immunohistochemistry (IHC) evaluation. After mice were killed,
lesional and nonlesional skin was excised and fixed in neutral-buffered formalin at
4uC overnight, embedded in paraffin, sectioned at 5 mm, and stained with
hematoxylin&eosin(H&E)andtoluidineblueforhistologicalanalysisasdescribed
17.
Immunohistochemistry assays were performed as previously described
17. A rat anti-
mouse major basic protein monoclonal antibody (a kind gift from Drs. Nancy and
James J. Lee, Mayo Clinic, Scottsdale, AZ) was applied to stain for eosinophils.
Similarly, for CD41 cells, rat anti-CD4 monoclonal antibody (Santa Cruz
Biotechnology Inc., Santa Cruz, CA) was applied at a 15100 dilution (1 mg /ml) or rat
anti-F4/80 antibody for evaluation of activated Langerhans cells and macrophages
(Panmacrophagemarkerclone:BM8,14-4801;eBioscience,SanDiego,CA)at15100
dilution (1 mg/ml). Appropriate ABC Staining Systems were used to visualize the
target proteins in the tissues (Santa Cruz Biotechnology).
Assessment of cytokine production by lymphocytes from draining lymph nodes
andspleen.SplenicCD4
1Tcellswereisolatedusinganti-CD4MACSMicroBeadsin
HBSS containing 5% FCS and 2 mM EDTA and positively selected on MS MACS
separation columns (Miltenyi Biotec, Auburn, CA) according to the manufacturer’s
instructions. Lymphocytes from draining lymph nodes (inguinal, axillaries and
subclavicle) and purified splenic CD41 cells were cultured in complete RPMI 1640
medium containing 5% FCS and activated using 96-well anti-CD3 plate (BD
bioscience) plus anti-CD28 (5 mg/ml) for 3 days. Supernatants were collected and
examined for cytokine production.
Measurement of cytokines, chemokines, and immunoglobulins. Cytokines and
chemokines in the skin, BAL fluid and cell culture supernatant samples were
measured using ELISA kits according to the manufacturer’s instructions (R&D
Systems, Minneapolis, MN).
Statistical analysis. Student’s t-test was used to determine the significance of
difference between two groups and one-way ANOVA was used for comparison
among multiple groups. All data were expressed as Mean6SEM. A difference of
P,0.05 was considered statistically significant.
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